Crispin Blunt
Reigate
My right hon. Friend is aware of the evidence on the use of psychedelic drugs for more effective mental health care. Last month Australia, having assessed the evidence on psilocybin, started the rescheduling process, and Australians suffering from depression will be able to access this medicine from July. In the USA, the Food and Drug Administration has recognised psilocybin as a breakthrough therapy for depression. In Canada, the special access programme allows physicians to request a licence for assisted therapy under certain conditions. Our drug laws remain based on a 50-year-old, unevidenced, prejudiced assessment and nothing else. The Home Office has never commissioned evidence on psilocybin. Does my right hon. Friend understand that this is a primary public health issue, on which he should lead?